Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Stomach (gastric) cancer
Trial Type:  Treatment
Results 1-25 of 73 for your search:
Start Over
Proton Beam Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Esophageal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1036, NCI-2012-00078, NCT01512589
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO27952, NCI-2013-00507, 2012-000660-22, NCT01641939
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15372, NCI-2015-00221, 2014-002240-40, I4T-MC-JVCU, NCT02314117
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
PARP inhibitor BMN-673 in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: D4190C00021, NCI-2015-00590, NCT02340975
A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy in Treating Patients with Metastatic Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, P09567, NCT01174121
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
Afatinib Dimaleate and Trastuzumab in Treating Patients with Refractory Metastatic Esophagus or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-166, NCI-2012-00414, NCT01522768
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TOG301, NCI-2012-00660, 2010-022164-12, NCT01573468
Start Over